The use of recombinant coagulation factor VIIa in patients undergoing surgical correction of scoliosis with the C-D method;Zastosowanie rekombinowanego czynnika krzepniȩcia VIIa u pacjentów z operacyjna̧ korekcja̧ skoliozy metoda̧ C-D

Ortopedia Traumatologia Rehabilitacja

Volumn 7, Issue 3, 2005, Pages 285-289

  Kolban, Maciej ^a,c   Bałachowska Kościołek, Ina ^b   Chmielnicki, Michał ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b OIOM SSP ZOZ Nad Dzieckiem I Mlodzieza   (Poland)

^c NONE   (Poland)

Author keywords

Recombinant factor VIIa; Scoliosis

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN;

ARTICLE; BLEEDING; BLOOD CLOTTING; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; PARAMETER; PROTHROMBIN TIME; SCOLIOSIS; SPINE SURGERY;

EID: 38549175209     PISSN: 15093492     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Brȩborowicz G., Sobieszczyk S., Szymankiewicz M.: Efficacy of recombinant activated factor VII (rF VII a Novoseven) in prenatalmedicine. Archives of prenatal medicine 2002;: 21-27.
2. Brodsky J., Dickson W., Erwin W. D., Rossi C. D.: Hypotensive anesthesis for scoliosis surgery in Jehovah's witnesses. Spine 1991; 16, (3): 304-306.
3. Bryson G. L., Laupaas A., Wells G. A.: Does acute normovolemic hemodilution reduce perioperative allogenic transfusion? A meta- analysis. Anest. Angl. 1998; (86): 9-15.
4. Chen A. X.: Perioperative management of anemia. Brit. J. of Anaesth. 1998; (81): 20-24.
5. Friedrich P. W., Henny C. P., Messelink E. J., Gerdink M. G., Keller T., Kurth K-H., Buller H. R., Levi M.: Effect of recombinat factor VII a on perioperative blood loss in patients undergoing retropubic prostatecomy: a double blind placebo controlled randomised trial. The Lancet 2003: 361: 201-205.
6. Gerotziafas G., Zervas K., Arzoglou P., Karavanggeli E., Parashou S., Dreden P. V., Clinistakis J., Samama M. M.: On the mechanism of action of recombinant activated factor VII administered to patients with severe thrombocytopenia and life- threatening haemorrhage: focus onprothrombin activation. Brit. J. Of Haematology 2002: (117): 705-708.
7. Brecker M. E., Monk T., Goodnough L. T.: A standardized method for calculating blood loss. Transfusion 1997: (37): 1070-74.
8. Monk G., Goodnough L. T., Brecher M. E.: Acute normovolemic hemodilution can replace preoperative autologus blood donations as a standard of care for radical prostatectomy. Anesth. Analg. 1997: 85: 953-958.
9. Meijer K., Hendriks H. G. D., Wolf J. T. M., Klompmaker J. J., Lisman T., Hagenaars A. A. M., Sloof M. J. H., Porte R. J., Meer J.: Recombinant facotr VII a in orthoptic liver transpantation: influence on parameters of coagulation and fibriolysis. Blood Coagulation and Fibrinolysis 2003: 14: (2): 169-173.
10. Monroe D. M., Hoffman M., Olivier M., Roberts J. A.: Platelet activity of high dose factor VII a is independent of tissue factor. Brit. J. of Haematolgy 199: 542-547.
11. Morenski J. D., Tobias J. D., Jimenez D. J.: Recombinant activated factor VII for cerebral injury- induced coagulopathy in pediatric patients. J. Neurosurgery 2003: (98) 611-616.
12. Sigbahn A.: Cellular consequences upon factor VII a binding to tissue factor. Haemostasis 2000: 30: 41-47.
13. Tobias J. D.: Synthetic factor VII a to treat dilutional coagulopathy during posterior spinal fusion in two children. Anesthesiology 2002: (6): 1522-50.
14. Mercuriali F. G., Inghilleri G.: Proposal of an algorhythm to help the choice of the best transfusion strategy. Current MedicalResearch and Opinion. 1996; 13, (8): 465-478.